X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2675) 2675
Publication (255) 255
Book Review (57) 57
Book Chapter (18) 18
Journal / eJournal (8) 8
Conference Proceeding (4) 4
Magazine Article (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
liposomal amphotericin-b (1747) 1747
humans (1729) 1729
index medicus (1081) 1081
antifungal agents - therapeutic use (949) 949
infectious diseases (694) 694
male (644) 644
pharmacology & pharmacy (609) 609
liposomal amphotericin b (576) 576
female (570) 570
microbiology (533) 533
amphotericin b (477) 477
amphotericin b - therapeutic use (448) 448
adult (437) 437
animals (424) 424
mycoses - drug therapy (390) 390
middle aged (382) 382
fungal-infections (370) 370
voriconazole (370) 370
aspergillosis (364) 364
antifungal agents - administration & dosage (346) 346
invasive fungal-infections (331) 331
treatment outcome (331) 331
amphotericin b - administration & dosage (298) 298
immunology (291) 291
mycoses (287) 287
antifungal agents (285) 285
child (280) 280
caspofungin (273) 273
aspergillosis - drug therapy (268) 268
visceral leishmaniasis (262) 262
aged (259) 259
adolescent (250) 250
care and treatment (242) 242
immunocompromised host (242) 242
mycology (242) 242
antifungal agents - adverse effects (237) 237
therapy (237) 237
health aspects (233) 233
fluconazole (231) 231
neutropenic patients (226) 226
risk factors (226) 226
invasive aspergillosis (224) 224
hematology (216) 216
diagnosis (214) 214
neutropenia (207) 207
infections (205) 205
candidiasis - drug therapy (204) 204
transplantation (204) 204
antifungal therapy (202) 202
persistent fever (198) 198
antifungal agents - pharmacology (193) 193
pharmacokinetics (192) 192
drug therapy, combination (186) 186
drug therapy (184) 184
liposomes (181) 181
oncology (177) 177
pediatrics (177) 177
efficacy (176) 176
leishmaniasis, visceral - drug therapy (174) 174
antiparasitic agents (172) 172
candidiasis (172) 172
antiprotozoal agents - therapeutic use (170) 170
echinocandins - therapeutic use (170) 170
pulmonary aspergillosis (169) 169
leishmaniasis (168) 168
child, preschool (167) 167
itraconazole (167) 167
cancer (166) 166
fungal infections (166) 166
kala-azar (165) 165
empirical antifungal therapy (164) 164
in-vitro (164) 164
echinocandins (163) 163
stem-cell transplantation (163) 163
double-blind (162) 162
medicine, general & internal (157) 157
ambisome (155) 155
invasive pulmonary aspergillosis (155) 155
mycoses - prevention & control (154) 154
triazoles - therapeutic use (154) 154
risk-factors (150) 150
mice (148) 148
research (147) 147
aspergillus (146) 146
epidemiology (146) 146
safety (146) 146
mortality (145) 145
antifungal agents - pharmacokinetics (143) 143
infant (142) 142
lipopeptides (142) 142
micafungin (142) 142
infection (138) 138
retrospective studies (138) 138
mucormycosis (135) 135
amphotericin b - adverse effects (132) 132
immunocompromised patients (130) 130
medicine & public health (129) 129
analysis (128) 128
lipid complex (128) 128
young adult (128) 128
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2401) 2401
Spanish (98) 98
French (90) 90
German (45) 45
Japanese (20) 20
Italian (10) 10
Turkish (5) 5
Polish (4) 4
Portuguese (3) 3
Russian (3) 3
Korean (2) 2
Czech (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Use of liposomal amphotericin B in bone marrow transplant, 12/2005
Increasing number of transplants worldwide has resulted in an increase in the incidence of fungal infections. Prolonged neutropenia, immunosuppression and... 
Bone marrow transplant, fungal infections, liposomal amphotericin B
Journal
Clinical Infectious Diseases, ISSN 1058-4838, 10/2006, Volume 43, Issue 7, pp. 917 - 924
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019, Volume 68, Issue Supplement_4, pp. S260 - S274
Abstract Since its introduction in the 1990s, liposomal amphotericin B (LAmB) continues to be an important agent for the treatment of invasive fungal diseases... 
clinical trial | Supplement | pharmacokinetics | liposomal amphotericin B | fungal infection | pharmacodynamics
Journal Article
Post-marketing study to assess the safety, tolerability and effectiveness of FungisomeTM: an Indian liposomal amphotericin B preparation, 12/2005
Background : In May 2003, an indigenously developed liposomal amphotericin B (FungisomeTM) was introduced in the Indian market for the treatment of systemic... 
Post marketing, Liposomal amphotericin B, Systemic fungal infections, FungisomeTM
Journal
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 03/2018, Volume 70, Issue 3, pp. 328 - 334
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019, Volume 68, Issue Supplement_4, pp. S244 - S259
Abstract The improved safety profile and antifungal efficacy of liposomal amphotericin B (LAmB) compared to conventional amphotericin B deoxycholate (DAmB) is... 
Supplement | pharmacokinetics | liposomal amphotericin B | LAmB | preclinical | pharmacodynamics
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 06/2019, Volume 565, pp. 447 - 457
Identifying the critical process parameters (CPPs) of a complex drug product manufacture and the associated impact on critical quality attributes (CQAs) is... 
Microfluidization | Amphotericin B | Liposomal formulation | AmBisome | Membrane lipids | Antiparasitic agents | Production processes
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 06/2019, Volume 63, Issue 6
In vitro pharmacokinetic/pharmacodynamic data of liposomal amphotericin B (L-AMB) were compared with animal data from neutropenic and nonneutropenic models of... 
azole resistance | VORICONAZOLE | liposomal amphotericin B | LIPID COMPLEX | DRUG CONCENTRATIONS | neutropenia | RANDOMIZED-TRIAL | MICROBIOLOGY | PHARMACODYNAMICS | DOSE-RESPONSE RELATIONSHIPS | MURINE MODEL | THERAPY | dose optimization | PHARMACOKINETICS | SUSCEPTIBILITY BREAKPOINTS | PHARMACOLOGY & PHARMACY | Aspergillus fumigatus
Journal Article
Journal Article
Journal Article